Dublin, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/lvqqw8/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

"Global Cancer Vaccine Market & Clinical Trial Insight" Report Highlights:

- Global Cancer Market Overview
- Emergence of Personalized Cancer Vaccines
- Platforms for Cancer Vaccines Delivery
- Mechanism of Cancer Vaccines
- Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
- Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
- Marketed Cancer Vaccines: 15 Vaccines
- Regulatory Framework for Cancer Vaccines Development & Marketing

Key Topics Covered:

1. Introduction to Cancer Vaacines

2. Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Therapy for Cancer Vaccines

4. Global Cancer Vaccines Market Overview
4.1 Current Market Scenario
4.2 Global Cancer Vaccine Drug Pipeline by Indication

5. Emergence of Personalized Cancer Vaccines

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics
7.1 Favorable Market Parameters
7.1.1 Pottential Demand for Cancer Vaccines
7.1.2 Public Cancer Vaccination Program
7.1.3 Advancements in Development Technology
7.1.4 Personalized Cancer Vaccines
7.1.5 Myriad of Demographs for Cancer Vaccine Development
7.2 Commercialization Challenges

8. Global Cancer Vaccine Market Future Outlook

9. Bladder Cancer Vaccine Clinical Pipeline Insight by Company & Phase
9.1 Phase-II

10. Blood Cancer Vaccine Clinical Pipeline Insight by Company & Phase
10.1 Research till Preregistration

11. Brain Cancer Vaccine Clinical Pipeline Insight by Company & Phase
11.1 Preclinical Till Phase-III

12. Breast Cancer Vaccine Clinical Pipeline Insight by Company & Phase
12.1 Preclinical till Phase-III

13. Cancer Vaccine Clinical Pipeline Insight by Company & Phase
13.1 Research till Phase-II

14. Cervical Cancer Vaccine Clinical Pipeline Insight by Company & Phase
14.1 Phase-II

15. Colorectal Cancer Vaccine Clinical Pipeline Insight by Company & Phase
15.1 Preclinical till Preregistration

16. Head and Neck Cancer Vaccine Clinical Pipeline Insight by Company & Phase
16.1 Preclinical till Phase-I/II

17. Liver Cancer Vaccine Clinical Pipeline Insight by Company & Phase
17.1 Phase-I till Phase-II

18. Lung Cancer Vaccine Clinical Pipeline Insight by Company & Phase
18.1 Preclinical till Phase-III

19. Oesophageal Cancer Vaccine Clinical Pipeline Insight by Company & Phase
19.1 Phase-III

20. Ovarian Cancer Vaccine Clinical Pipeline Insight by Company & Phase
20.1 Preclinical till Phase-III

21. Pancreatic Cancer Vaccine Clinical Pipeline Insight by Company & Phase
21.1 Reseach till Phase-III

22. Prostate Cancer Vaccine Clinical Pipeline Insight by Company & Phase
22.1 Preclinical till Phase-III

23. Renal Cancer Vaccine Clinical Pipeline Insight by Company & Phase
23.1 Phase-I till Phase-III

24. Sarcoma Vaccine Clinical Pipeline Insight by Company & Phase
24.1 Phase-II

25. Skin Cancer Vaccine Clinical Pipeline Insight by Company & Phase
25.1 Preclinical till Phase-III

26. Solid Tumours Vaccine Clinical Pipeline Insight by Company & Phase
26.1 Preclinical till Phase-II

27. Multiple Cancer Vaccine Clinical Pipeline Insight by Company & Phase
27.1 Preclinical till Phase-III

28. Marketed Cancer Vaccine Clinical Insight by Company & Indication
28.1 Bladder Cancer
28.1.1 BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®)
28.1.2 Bladder Cancer Vaccine (PACIS®)
28.1.3 Bladder Cancer Vaccine - Organon Teknika

28.2 Cervical Cancer
28.2.1 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

28.3 Lung Cancer
28.3.1 BV NSCLC 001
28.3.2 Cadi 05 (Immuvac® & Mycidac-C)
28.3.3 Racotumomab (Vaxira®)

28.4 Pancreatic Cancer
28.4.1 Tertomotide (LucaVax)

28.5 Prostate Cancer
28.5.1 Sipuleucel-T (Provenge®)

28.6 Renal Cancer
28.6.1 Renal Cancer Vaccine (Reniale®)
28.6.2 Vitespen (Oncophage®)

28.7 Skin Cancer
28.7.1 Melanoma Vaccine (MVax®)
28.7.2 Melanoma Vaccine (Melacine®)

28.8 Multiple Cancer
28.8.1 Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)
28.8.2 Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

29. Discontinued & Suspended Cancer Vaccine Drug Clinical Pipeline Insight
29.1 No Development Reported
29.2 Discontinued
29.3 Suspended

30. FDA Regulatory Framework for Cancer Vaccines Development & Marketing
30.1 Considerations for both Early and Late Phase Clinical Trials
30.1.1 Patient Population
30.1.2 Monitoring the Immune Response
30.1.3 Biomarkers as Evidence Of Efficacy
30.1.4 Adjuvants Used To Stimulate Immune Response
30.1.5 Multi-Antigen Vaccines
30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
30.1.7 Concomitant and Subsequent Therapies

30.2 Considerations for Early Phase Clinical Trials
30.2.1 Starting Dose and Dosing Schedule
30.2.2 Booster and Maintenance Therapy
30.2.3 Dose Escalation
30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development

30.3 Considerations for Late Phase Clinical Trials
30.3.1 Safety Profile from Early Phase Clinical Trials
30.3.2 Endpoints
30.3.3 Statistical Issues
30.3.4 Control Issues
30.3.5 Delayed Vaccine Effect
30.3.6 Autologous Vaccine Trials
30.3.7 Accelerated Approval Regulations

31. Competitive Landscape: Business Overview & Product Pipeline
31.1 Advaxis
31.2 AVAX Technologies
31.3 Celldex Therapeutics
31.4 Dendreon Corporation
31.5 Galena Biopharma
31.6 GlaxoSmithKline
31.7 ImmunoCellular Therapeutics
31.8 ImmunoGen
31.9 Inovio Pharmaceuticals
31.10 KAEL-GemVax
31.11 Liponova
31.12 MedImmune
31.13 Merck
31.14 NeoStem Oncology
31.15 NewLink Genetics
31.16 Northwest Biotherapeutics
31.17 Novartis
31.18 Peregrine Pharmaceuticals
31.19 Recombio
31.20 Roche
31.21 Sanofi
31.22 Seattle Genetics
31.23 Valeant Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/lvqqw8/global_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Clinical Trials, Cancer Vaccines

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.